DexCom, Inc.
| Company Name | DexCom, Inc. |
| Stock Symbol | DXCM |
| Class Period | January 08, 2024 to July 25, 2024 |
| Lead Plaintiff Motion Deadline | October 21, 2024 |
On July 25, 2024, after the market closed, DexCom announced its second quarter 2024 financial results, including $1.004 billion revenue, in a press release stating the Company’s “execution did not meet [its] high standards.” The Company also lowered its full year 2024 guidance, expecting between $4 billion and $4.05 billion revenue, due to “certain unique items impacting 2024 seasonality.”
On this news, the Company’s stock price fell $43.85, or 40.7%, to close at $64.00 per share on July 26, 2024, thereby injuring investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was not truly equipped to execute on its perceived growth potential as it relied far too heavily on its ability to attract new customers while keeping existing distribution channels afloat; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Submit Your Information
If you suffered a loss on your DexCom, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.